Research programme: liver diseases therapy - Kadmus Pharmaceuticals
Alternative Names: KDS-5104; Liver diseases therapy research programme - Kadmus PharmaceuticalsLatest Information Update: 16 Jul 2016
At a glance
- Originator Kadmus Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Liver disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Liver-disorders in USA
- 10 Aug 2005 Preclinical trials in Liver disorders in USA (unspecified route)